PCN206 PATIENT-REPORTED REAL-WORLD TREATMENT PATTERNS FOR MELANOMA IN THE UK MEASURED USING A DIGITAL 'BRING YOUR OWN DEVICE' PLATFORM

Abstract

Real-world melanoma clinical practice is changing rapidly with the introduction of new treatments. This analysis examined patient-reported treatment patterns for melanoma in UK real-world practice, including choice and duration of treatment, consultation frequency, and application of treatment guidelines, in close to real-time. Adults with any type or stage of melanoma were recruited to an observational study exploring the real-world impact of melanoma, conducted in collaboration with the patient advocacy group Melanoma UK. Data were collected via a bespoke ‘bring your own device’ app co-created with patients and Melanoma UK. Informed consent was obtained via the app, and ethical approval was obtained. Participants answered one-time questions relating to treatment patterns: current and previous treatments (drugs and surgery), where they lived/were treated, and frequency of consultations. Data were analyzed using R software; statistical analysis aimed to identify associations between treatment and other patient characteristics, including demographics and Eastern Cooperative Oncology Group (ECOG) performance status. Treatment patterns were compared with current guidelines. Of the 219 (total registered: 396) patients who specified current disease stage, 45% were stage 3 or 4; 83% reported a latest ECOG performance status of unknown or 0. Current real-world treatment of melanoma in the UK was broadly consistent with published guidance; immunotherapies dominated treatment at stage 4 (ipilimumab 35% patients; nivolumab 23% patients). 178 patients provided their location, allowing regional differences in treatment patterns to be identified. Radiotherapy was more common in North- (16% of patients) and South-West (14% of patients) regions, but was not used to treat any patients in the East Midlands and South-Central regions. Centers treating the most patients included the Christie, Royal Marsden and Nottingham Hospitals NHS Trusts. Melanoma treatment in the UK real-world setting broadly follows published guidelines. Availability of close to real-time data offers the opportunity to quickly identify any inequalities, improving care.